Dr. Gettinger on PD-1 Inhibitor BMS-936558 in NSCLC

Video

Scott Gettinger, MD, from the Yale School of Medicine, discusses updated results from a phase I trial that examined the novel immunotherapy BMS-936558 in patients with NSCLC and other solid tumors.

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, discusses updated results from a phase I trial that examined the novel immunotherapy BMS-936558 in patients with non-small cell lung cancer and other solid tumors.

The study analyzed the programmed death-1 (PD-1) pathway as a target in several different cancers. Heavily pretreated patients received BMS-936558 intravenously at doses of 0.1 to 10.0 mg/kg during dose-escalation and/or cohort expansion. Gettinger was surprised that response rates were so high, considering the patients were heavily pretreated. The updated results showed an initial response of 18% in non-small cell lung cancer.

With 122 patients available to assess, the response by RECIST criteria was 16% for patients with NSCLC. Gettinger adds that patients who did respond saw long lasting responses, including some patients beyond one year.

When using immunotherapies, Gettinger says, there is sometimes a delay in when a regression can be seen on a radiograph, which may have impacted the overall results.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD